GS 19
Alternative Names: GS-19; GT-90008Latest Information Update: 28 Sep 2024
At a glance
- Originator Gensun Biopharma
- Developer Gensun Biopharma; Suzhou Kintor Pharmaceuticals
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for preclinical development in Solid-tumours in USA (Parenteral)
- 17 Jan 2022 Phase-I clinical trials in Solid tumours in China (Parenteral) (Suzhou Kintor Pharmaceuticals pipeline, January 2022)
- 25 Oct 2021 GS 19 - Gensun Biopharma is available for licensing as of 25 Oct 2021. https://www.gensunbiopharma.com/contact